Alex Gough

Akrivia Health was founded to answer a critical question: Why is mental health and dementias research still decades behind? Spun out of the NHS and Oxford University in 2019, we’re focused on curating the world’s most in-depth neuropsychiatric and neurodegenerative dataset – linking structured and unstructured EHRs with genomic and longitudinal insights. Because what is urgently needed in this space is faster access to better quality data. Our AI-enabled solutions apply advanced NLP to extract deep phenotypic signals from clinical notes, enabling patient stratification, outcome tracking, and real-world evidence generation. Through this, we enable researchers, pharma, and healthcare providers to evaluate treatment effectiveness, optimise clinical trials, and drive precision care. Join us to transform the future of mental health and dementias and improve lives – one data point at a time.

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Sequins (sequencing spike-ins) are synthetic nucleic acid controls that directly mirror naturally occurring sequences. Our innovative design enables representation of almost any genomic feature, in any organism with a reference genome. Sequins retain the same nucleotide composition as the natural sequence and enable accurate representation of genomic complexity without compromising integrity of samples and results.

Akrivia Health was founded to answer a critical question: Why is mental health and dementias research still decades behind? Spun out of the NHS and Oxford University in 2019, we’re focused on curating the world’s most in-depth neuropsychiatric and neurodegenerative dataset – linking structured and unstructured EHRs with genomic and longitudinal insights. Because what is urgently needed in this space is faster access to better quality data. Our AI-enabled solutions apply advanced NLP to extract deep phenotypic signals from clinical notes, enabling patient stratification, outcome tracking, and real-world evidence generation. Through this, we enable researchers, pharma, and healthcare providers to evaluate treatment effectiveness, optimise clinical trials, and drive precision care. Join us to transform the future of mental health and dementias and improve lives – one data point at a time.

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.